|
Market Closed -
Nasdaq
21:00:00 30/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.650 USD | -1.27% |
|
-17.87% | -91.87% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
Company Valuation: Immutep Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.7 | 374 | 420.2 | 350.5 | 78.11 | 50.11 | - | - |
| Change | - | 50.99% | 12.36% | -16.6% | -77.72% | -35.85% | - | - |
| Enterprise Value (EV) 1 | 169.2 | 251.4 | 259.4 | 284.2 | 14.43 | -4.493 | 16.27 | -9.56 |
| Change | - | 48.63% | 3.18% | 9.55% | -94.92% | -131.13% | 462.15% | -158.75% |
| P/E | -7.65x | -7.05x | -8.29x | -5.69x | -0.98x | -2x | -3.09x | -4.64x |
| PBR | 2.62x | 2.74x | 2.26x | 2.43x | 1.27x | 2.72x | 5.67x | 0.69x |
| PEG | - | -0.4x | 0.4x | -0.3x | -0x | 0x | 0.1x | 0.1x |
| Capitalization / Revenue | 36.7x | 71.9x | 53.6x | 33.9x | 3.23x | 12.5x | 16.7x | 25.1x |
| EV / Revenue | 25x | 48.3x | 33.1x | 27.5x | 0.6x | -1.12x | 5.42x | -4.78x |
| EV / EBITDA | -5.63x | -6.65x | -6.42x | -4.82x | -0.19x | 0.16x | -0.74x | 0.56x |
| EV / EBIT | -5.27x | -6.31x | -6.08x | -4.63x | -0.18x | 0.15x | -0.45x | 0.26x |
| EV / FCF | -5.59x | -7.09x | 7.46x | -4.58x | -0.26x | 0.18x | -0.76x | 0.71x |
| FCF Yield | -17.9% | -14.1% | 13.4% | -21.8% | -385% | 556% | -132% | 141% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0379 | -0.0447 | -0.0356 | -0.0422 | -0.0539 | -0.017 | -0.011 | -0.00733 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 6.758 | 5.2 | 7.839 | 10.33 | 24.17 | 4 | 3 | 2 |
| EBITDA 1 | -30.05 | -37.81 | -40.42 | -59.01 | -76.76 | -27.67 | -22.03 | -17.03 |
| EBIT 1 | -32.12 | -39.88 | -42.69 | -61.4 | -79.24 | -29.6 | -36.27 | -36.36 |
| Net income 1 | -32.21 | -39.9 | -42.72 | -61.43 | -79.3 | -26.1 | -30.47 | -31.07 |
| Net Debt 1 | -78.54 | -122.6 | -160.8 | -66.3 | -63.67 | -54.6 | -33.83 | -59.67 |
| Reference price 2 | 0.2900 | 0.3150 | 0.2950 | 0.2400 | 0.0530 | 0.0340 | 0.0340 | 0.0340 |
| Nbr of stocks (in thousands) | 854,123 | 1,187,306 | 1,424,548 | 1,460,390 | 1,473,721 | 1,473,721 | - | - |
| Announcement Date | 31/08/22 | 29/08/23 | 29/08/24 | 28/08/25 | 30/08/26 | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.87x | 7.45x | 14.96x | 1.42% | 71.53B | |
| 31.24x | 9x | 28.05x | 0.04% | 60.12B | |
| 34.13x | 6.11x | 18.31x | 0.95% | 48.85B | |
| 34.64x | 3.34x | 14.41x | -.--% | 44.28B | |
| -21.08x | 228.26x | -22.72x | -.--% | 43.83B | |
| 47.85x | 5.53x | 30.37x | -.--% | 41.53B | |
| 27.07x | 7.8x | 20.09x | 0.42% | 30.13B | |
| 32.39x | 6.91x | 17.94x | -.--% | 27.98B | |
| -70.94x | 13.62x | -69.42x | -.--% | 25.25B | |
| Average | 15.13x | 32.00x | 5.78x | 0.32% | 43.72B | |
| Weighted average by Cap. | 19.23x | 31.83x | 9.93x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
- Valuation Immutep Limited
Select your edition
All financial news and data tailored to specific country editions
